By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioTime today announced that its majority-owned subsidiary OncoCyte has received $10 million in a new round of equity financing, which it will use to further develop diagnostics and therapeutics for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.